01/21/2026

ASCO’s January Coding Tip of the Month: DPD/DPYD Testing

Recent FDA label updates (2024 for fluorouracil; 2025 for capecitabine) and revised ASCO and NCCN guidelines now emphasize testing for dihydropyrimidine dehydrogenase (DPD or DPYD) deficiency to avoid severe drug toxicity. The following codes may be used when reporting DPD/DPYD-specific testing:

• 81232: DPYD Gene Analysis (Common variants such as *2A, *4, *5, *6). Use this for targeted metabolism testing for 5-FU and capecitabine.

• 0533U: Multi-Gene Panel for drug metabolism, reporting metabolizer status and transporter function. (Includes DPYD plus ABCG2, CYP2B6, CYP2C9, CYP2C19, CYP2C, CYP2D6, CYP3A5, CYP4F2, G6PD, GGCX, NUDT15, SLCO1B1, TPMT, UGT1A1, VKORC1).

If DPYD analysis is performed as part of a larger liquid biopsy or comprehensive genomic profile, different panel codes may apply. Ensure the code matches the specific scope of the test ordered.

Be sure to bookmark the Coding and Reimbursement page to view more updates as they are added.